Net Income (Loss) Attributable to Parent in USD of Horizon Therapeutics Public Ltd Co from Q2 2010 to Q2 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Horizon Therapeutics Public Ltd Co quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from Q2 2010 to Q2 2023.
  • Horizon Therapeutics Public Ltd Co Net Income (Loss) Attributable to Parent for the quarter ending 30 Jun 2023 was $127M, a 108% increase year-over-year.
  • Horizon Therapeutics Public Ltd Co Net Income (Loss) Attributable to Parent for the twelve months ending 30 Jun 2023 was $438M, a 42.7% decline year-over-year.
  • Horizon Therapeutics Public Ltd Co annual Net Income (Loss) Attributable to Parent for 2022 was $521M, a 2.43% decline from 2021.
  • Horizon Therapeutics Public Ltd Co annual Net Income (Loss) Attributable to Parent for 2021 was $534M, a 37.1% increase from 2020.
  • Horizon Therapeutics Public Ltd Co annual Net Income (Loss) Attributable to Parent for 2020 was $390M, a 32% decline from 2019.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

Horizon Therapeutics Public Ltd Co Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2023 $438M $127M +$66.1M +108% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2023
Q1 2023 $372M $54.7M -$150M -73.2% 01 Jan 2023 31 Mar 2023 10-Q 08 Aug 2023
Q4 2022 $521M $120M -$52.8M -30.5% 01 Oct 2022 31 Dec 2022 10-K 01 Mar 2023
Q3 2022 $574M $136M -$191M -58.4% 01 Jul 2022 30 Sep 2022 10-Q 02 Nov 2022
Q2 2022 $765M $61M -$97.1M -61.4% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023
Q1 2022 $862M $204M +$328M 01 Jan 2022 31 Mar 2022 10-Q 08 Aug 2023
Q4 2021 $534M $173M -$17.4M -9.12% 01 Oct 2021 31 Dec 2021 10-K 01 Mar 2023
Q3 2021 $552M $327M +$33.7M +11.5% 01 Jul 2021 30 Sep 2021 10-Q 02 Nov 2022
Q2 2021 $518M $158M +$238M 01 Apr 2021 30 Jun 2021 10-Q 02 Nov 2022
Q1 2021 $280M -$123M -$110M -808% 01 Jan 2021 31 Mar 2021 10-Q 02 Nov 2022
Q4 2020 $390M $191M -$402M -67.9% 01 Oct 2020 31 Dec 2020 10-K 24 Feb 2021
Q3 2020 $792M $293M +$275M +1506% 01 Jul 2020 30 Sep 2020 10-Q 03 Nov 2021
Q2 2020 $517M -$80M -$74.9M -1463% 01 Apr 2020 30 Jun 2020 10-Q 03 Nov 2021
Q1 2020 $592M -$13.6M +$19.3M +58.6% 01 Jan 2020 31 Mar 2020 10-Q 03 Nov 2021
Q4 2019 $573M $593M +$491M +483% 01 Oct 2019 31 Dec 2019 10-K 24 Feb 2021
Q3 2019 $81.9M $18.2M -$15.1M -45.4% 01 Jul 2019 30 Sep 2019 10-K 24 Feb 2021
Q2 2019 $97M -$5.12M +$19.6M +79.3% 01 Apr 2019 30 Jun 2019 10-K 24 Feb 2021
Q1 2019 $77.4M -$32.9M +$116M +77.9% 01 Jan 2019 31 Mar 2019 10-K 24 Feb 2021
Q4 2018 -$38.4M $102M +$140M 01 Oct 2018 31 Dec 2018 10-K 26 Feb 2020
Q3 2018 -$178M $33.4M +$97.1M 01 Jul 2018 30 Sep 2018 10-K 26 Feb 2020
Q2 2018 -$275M -$24.8M +$185M +88.2% 01 Apr 2018 30 Jun 2018 10-K 26 Feb 2020
Q1 2018 -$460M -$149M -$58.3M -64.5% 01 Jan 2018 31 Mar 2018 10-K 26 Feb 2020
Q4 2017 -$402M -$38.2M +$91M +70.4% 01 Oct 2017 31 Dec 2017 10-K 27 Feb 2019
Q3 2017 -$493M -$63.7M -$57.9M -986% 01 Jul 2017 30 Sep 2017 10-K 27 Feb 2019
Q2 2017 -$435M -$209M -$224M -1497% 01 Apr 2017 30 Jun 2017 10-K 27 Feb 2019
Q1 2017 -$210M -$90.3M -$44.9M -99% 01 Jan 2017 31 Mar 2017 10-K 27 Feb 2019
Q4 2016 -$166M -$129M -$153M -639% 01 Oct 2016 31 Dec 2016 10-K 27 Feb 2019
Q3 2016 -$12.3M -$5.87M -$9.15M -279% 01 Jul 2016 30 Sep 2016 10-Q 06 Nov 2017
Q2 2016 -$3.15M $15M -$16.8M -52.9% 01 Apr 2016 30 Jun 2016 10-Q 07 Aug 2017
Q1 2016 $13.7M -$45.4M -$25.9M -132% 01 Jan 2016 31 Mar 2016 10-Q 08 May 2017
Q4 2015 $39.5M $24M +$55.6M 01 Oct 2015 31 Dec 2015 10-K 28 Feb 2018
Q3 2015 -$16.1M $3.28M +$1.21M +58.8% 01 Jul 2015 30 Sep 2015 10-Q 07 Nov 2016
Q2 2015 -$17.3M $31.8M +$59.6M 01 Apr 2015 30 Jun 2015 10-Q 08 Aug 2016
Q1 2015 -$76.9M -$19.6M +$187M +90.5% 01 Jan 2015 31 Mar 2015 10-Q 09 May 2016
Q4 2014 -$264M -$31.6M 01 Oct 2014 31 Dec 2014 10-K 27 Feb 2017
Q3 2014 $2.06M 01 Jul 2014 30 Sep 2014 10-Q 06 Nov 2015
Q2 2014 -$27.8M 01 Apr 2014 30 Jun 2014 10-Q 07 Aug 2015
Q1 2014 -$206M 01 Jan 2014 31 Mar 2014 10-Q 08 May 2015
Q3 2011 -$17.2M -$4.74M -38% 01 Jul 2011 30 Sep 2011 10-Q 14 Nov 2011
Q2 2011 -$11.6M -$18.5M -269% 01 Apr 2011 30 Jun 2011 10-Q 02 Sep 2011
Q3 2010 -$12.5M 01 Jul 2010 30 Sep 2010 10-Q 14 Nov 2011
Q2 2010 $6.88M 01 Apr 2010 30 Jun 2010 10-Q 02 Sep 2011

Horizon Therapeutics Public Ltd Co Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2022 $521M -$13M -2.43% 01 Jan 2022 31 Dec 2022 10-K 01 Mar 2023
2021 $534M +$145M +37.1% 01 Jan 2021 31 Dec 2021 10-K 01 Mar 2023
2020 $390M -$183M -32% 01 Jan 2020 31 Dec 2020 10-K 01 Mar 2023
2019 $573M +$611M 01 Jan 2019 31 Dec 2019 10-K 01 Mar 2022
2018 -$38.4M +$312M +89% 01 Jan 2018 31 Dec 2018 10-K 24 Feb 2021
2017 -$350M -$185M -111% 01 Jan 2017 31 Dec 2017 10-K 26 Feb 2020
2016 -$166M -$205M -519% 01 Jan 2016 31 Dec 2016 10-K 27 Feb 2019
2015 $39.5M +$303M 01 Jan 2015 31 Dec 2015 10-K 28 Feb 2018
2014 -$264M -$115M -76.9% 01 Jan 2014 31 Dec 2014 10-K 27 Feb 2017
2013 -$149M -$61.2M -69.7% 01 Jan 2013 31 Dec 2013 10-K 29 Feb 2016
2012 -$87.8M +$25.5M +22.5% 01 Jan 2012 31 Dec 2012 10-K/A 02 Mar 2015
2011 -$113M -$86.2M -318% 01 Jan 2011 31 Dec 2011 10-K 13 Mar 2014
2010 -$27.1M 01 Jan 2010 31 Dec 2010 10-K 18 Mar 2013
* An asterisk sign (*) next to the value indicates that the value is likely invalid.